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Abstract
Background: Dendritic cells (DC) and regulatory cells (Treg) play pivotal roles in controlling both normal and autoimmune
adaptive immune responses. DC are the main antigen-presenting cells to T cells, and they also control Treg functions. In this
study, we examined the frequency and phenotype of DC subsets, and the frequency and function of Treg from patients with
ANCA-associated vasculitis (AAV).
Methodology/Principal Findings: Blood samples from 19 untreated patients with AAV during flares and before any
immunosuppressive treatment were analyzed, along with 15 AAV patients in remission and 18 age-matched healthy
controls. DC and Treg numbers, and phenotypes were assessed by flow cytometry, and in vitro suppressive function of Treg
was determined by co-culture assay. When compared to healthy volunteers, absolute numbers of conventional and
plasmacytoid DC were decreased in AAV patients. During the acute phase this decrease was significantly more pronounced
and was associated with an increased DC expression of CD62L. Absolute numbers of Treg (CD4
+CD25
highCD127
low/2 Tcells)
were moderately decreased in patients. FOXP3 and CD39 were expressed at similar levels on Treg from patients as
compared to controls. The suppressive function of Treg from AAV patients was dramatically decreased as compared to
controls, and this defect was more pronounced during flares than remission. This Treg functional deficiency occurred in the
absence of obvious Th17 deviation.
Conclusion: In conclusion, these data show that AAV flares are associated with both a decrease number and altered
phenotype of circulating DC and point to a role for Treg functional deficiency in the pathogenesis of AAV.
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Introduction
Antineutrophil cytoplasmic antibodies (ANCA)-associated vas-
culitides (AAV) are the most common primary systemic small-
vessel vasculitis in adults. AAV includes microscopic polyangiitis
(MPA), Wegener’s granulomatosis (WG), and Churg-Strauss
syndrome (CSS). ANCA are directed against constituents of
primary granules from neutrophils and against monocytic
lysosomes. These can be directed against proteinase 3 (PR3) [1],
and against myeloperoxidase (MPO) [2]. PR3 ANCA are mostly
found in patients with WG, whereas ANCA with specificity for
MPO are associated with MPA and CSS. It is now well accepted
that ANCA are directly involved in AAV pathogenesis. ANCA
correlate with disease activity [3], and their pathogenic role has
been demonstrated in vitro and in vivo [4,5]. More recently,
ANCA with specificity to lysosomal associated membrane protein
2 (LAMP2) were described; interestingly these ANCA appeared to
cross react with fimbriated bacteria suggesting a molecular
mimicry mechanism [6].
The involvement of T-cells in AAV has also been suggested
by several studies [7,8,9]. It is well known that ANCA have a T-
dependent isotype [10]. Reduced numbers of blood CD4
+ T
cells were observed in AAV, together with a skew toward
memory population, which could be the consequence of a
persistent activation due to recurrent exposure to an unknown
antigen [11,12]. Recently Abdulahad et al. reported a functional
defect in CD4
+ Regulatory T cells (Treg) in patients with
Wegener’s granulomatosis during remission [13]. So called
naturally occurring Treg (CD4
+CD25
+FOXP3
+ Tc e l l s )a r e
essential for maintaining peripheral tolerance, preventing
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es. These cells suppress the activation and expansion of self-
reactive T cells [14], and reduced functional activity of Treg
results in an increased susceptibility to autoimmune disease. As
t h ep e r c e n t a g eo fT r e gi np a t i e nt’s peripheral blood can be
unaltered when compared with healthy controls, it has been
suggested that it is mainly the defective Treg function, rather
than their numbers, that contributes to disease development
[15]. Patients with multiple sclerosis, polyglandular syndrome
type II, active rheumatoid arthritis and type-I diabetes show a
significant decrease in the suppressive function of their Treg as
compared with cells from healthy donors [15,16,17]. In
addition, in some autoimmune diseases, reduced numbers of
Treg have been observed in the peripheral blood of patients.
However, in these cases, the recruitment or migration of Treg
from the blood to the inflammatory site may be responsible for
the decreased number of Treg in peripheral blood [18]. Thus,
quantitative or qualitative defects of Treg may be observed in
human autoimmune diseases. Moreover, recent studies suggest
that a CD39
+ subset of Treg could be involved in the control of
autoimmune disease-mediated inflammation [19,20]. Fletcher
et al reported that these CD39
+FOXP3
+ Treg suppressed IL-17
production and were impaired in multiple sclerosis [21].
Dendritic cells (DC) are the key antigen-presenting cells
controlling the initiation of the T cell response [22]. DC are not
only critical for the induction of primary immune responses, but
may also be important for the induction of immunological
tolerance, as well as for the regulation of the type of T cell-
mediated immune response [23]. In the blood, DC are usually
divided into two main populations: conventional DC (also know as
myeloid DC, mDC), which are actually heterogeneous, and
plasmacytoid DC (pDC) [24,25]. Whereas mDC produce large
amounts of IL-12 and induce Th1 and cytotoxic responses, pDC
have a strong capacity for secreting type I interferon in response to
viruses [26]. pDC also express the IL-3 receptor achain (CD123)
which is necessary for their survival and differentiation. Involve-
ment of specific receptors on DC in response to particular self-
antigens may contribute to the development of an autoimmune
vasculitis. Interestingly, Csernok et al. showed that PR3 can induce
DC maturation in vitro, and can license them for Th1 response
potentially favouring granuloma formation in WG [27].
In the present study we assessed firstly, the quantitative and
phenotypic modifications of peripheral blood DC, and secondly
the numbers, phenotype and function of Treg from patients with
ANCA-associated vasculitis in remission or in acute phase
compared with age matched healthy individuals. As DC are
pivotal in the control of Treg, we hypothesize that both could have
quantitative or functional defect in AAV.
Results
Decreased numbers of circulating pDC and mDC during
AAV
Circulating DC are a rare population of blood leukocytes (,1%
of PBMC), which can be identified as Lin
2 HLA-DR
+ cells. Two
subsets of DC can be separated on the basis of CD11c and CD123
expression: so-called myeloid or conventional DC that are CD11c
+
CD123
2 and plasmacytoid DC (pDC) that are CD11c
2 CD123
+
(Fig. 1A). The numbers of circulating DC subsets were assessed on
fresh whole blood samples from controls and patients after staining
with CD45, Lin, HLA-DR, CD11c and CD123, and using
calibrated beads. When compared to healthy controls (HC),
AAV-patients exhibited a significant decrease in total DC numbers
both during the acute phase (AP) and the remission phase (RP)
(7.5 DC/mL vs 20 DC/mL, p,0.0001 ; 15.5 cells/mL vs 20 DC/mL;
p=0.0448). Moreover, the decrease in DC between the 2 groups
was significant, with a more pronounced decrease seen during the
acute phase than during the remission phase (7.5 DC/mL vs 15.5
cells/mL p=0.0008). The same significant decrease was observed
for mDC between HC and RP (p=0.0301), between HC and AP
(p,0.0001), and alsobetween RP and AP (p=0.0015). For pDC the
decrease was significant only in AP versus HC (p=0.0001), and AP
versus RP (p=0.0107) (Fig. 1B).
Increased expression of CD62L on DC during acute phase
of AAV
To address the activation and the maturation status of
circulating DC, we assessed the expression of CD86, CD62L
and CCR7 on blood DC. CD86 (B7-2) is an important
costimulatory molecule that is upregulated on mature DC.
CCR7 is a crucial homing molecule for addressing DC to
secondary lymphoid organs and CD62L was shown mediate pDC
recruitment to inflamed lymph nodes [28] and in vivo monocyte-
derived DC migration to lymph nodes [29].
It is well known that blood DC have a semi mature phenotype
characterised by an expression of CD86 and CCR7 but a lack of
CD83. There was no significant difference between AAV patients
and controls regarding the expression of CD86, and CCR7 on
DC. The large majority of mDC, but few pDC, were CD86
+
(94%, 93%, 90% on mDC, and 28%, 31%, 31% on pDC in HC,
RP, AP respectively). The expression levels of CD86 on DC were
equivalent for patients and controls. Between 82 and 92% of DC
were CCR7
+ and the expression levels were not significantly
different between patients and controls (data not shown). No
surface expression of CD83 was detected on DC from patients or
controls (data not shown). Although virtually all mDC and pDC
expressed CD62L in the three groups of individuals, we observed a
significant increase in CD62L expression levels on both pDC and
mDC from acute phase patients as compared to patients in
remission (p=0.0002 and p=0.0030 respectively). This difference
was more pronounced for pDC than for mDC (Fig. 1C).
Decreased numbers but equivalent frequencies of
circulating Treg cells during acute phase of AAV
The frequencies and the absolute numbers of circulating Treg
were assessed in whole blood samples. Tregs were identified
among CD4
+CD3
+ cells as CD25
highCD127
low/2 cells. The gating
strategy use in controls and AAV patients is shown in figure 2.
Previous studies have shown that CD25 expression was upregu-
lated on CD4
+ T cells from AAV patients [12,30] as in other
inflammatory disease. This was indeed the case in our study with
CD4
+ T cells from AP patients. In contrast, CD25/CD127 profiles
for remission patients were similar to that observed in controls
(Fig. 2A). Therefore, in most of acute phase patients, a slight
modification of the Treg gate was necessary to account for this
increase in CD25 expression (Fig. 2A). We confirmed using
PBMC that these gated cells expressed similar and high levels of
FOXP3 in controls and in AAV-patients (Fig. 2B). Although the
frequencies of Treg among CD4
+ T cells were not significantly
different between controls and patients (Fig. 3A), a significant
decrease in absolute numbers of Treg was observed in patients
during acute phase as compared to control individuals (Fig. 3.B;
p= 0.0003). However, this decrease was correlated with the
lymphopenia usually observed in these patients. The frequencies
and levels of FOX-P3 expression in CD3
+CD4
+CD25
highC-
D127
low/2 cells were compared on PBMC and we did not
observed any differences between controls and AAV patients
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of CD39 in CD3
+CD4
+CD25
highCD127
low/2 Treg cells on
cryopreserved PBMC. Again, no differences were observed
between the 3 groups with 40%, 45% and 42% of Treg expressing
CD39 in controls, acute phase AAV and remission AAV,
respectively (Fig. 3D).
Defective suppressive function of circulating Treg cells in
AAV-patients in remission and in acute phase
We then addressed the in vitro suppressive activity of Treg using
a polyclonal stimulation assay. Treg were isolated by FACS as
CD4
+CD25
high and CD127
low/2 cells (Fig. 4A). T cells were
stimulated by anti-CD3 in the presence of soluble anti-CD28
mAb. Treg alone incorporated less than 5,000 cpm. Means of
proliferation for T responder cells alone were 63,200 for healthy
donors, 41,760 for remission patients and 56,600 for acute phase
patients. For co-culture assays, the proliferation was higher for
patients in acute phase and in remission (respectively 50,769 and
27,020) than in controls (14,808) (Fig. 4B). As expected, Treg
from controls exhibited a potent suppressive activity in vitro when
mixed at 1:1 ratio with effector T cells. In contrast, Treg from
patients exhibited a decrease in their suppressive activity. Acute
phase patients presented a significant decrease in suppressive
activity as compared to both controls (7% vs 78%; p,0.0001) and
the remission group (7% vs 37%; p=0.0301). In addition, the
remission group exhibited a decreased Treg suppressive function
as compared to controls (37% vs 78%. p=0.0008) (Fig. 4C). To
determine whether the observed defect in suppression was related
to patient Treg intrinsic defective suppression or to a resistance of
patient effector cells to Treg-mediated suppression, we performed
Figure 1. Characterization and count of dendritic cells using flow cytometry. A, Gating strategy for identification of DC subsets, and
expression of CD86, CD62L and CCR7 (blue line) vs. isotype control (red line) on DC subset. B, Quantification of DC, myeloid DC and plasmacytoid DC
using flow cytometry is shown for healthy controls (HC ; n=18), remission phase (RP ; n=15) and acute phase (AP ; n=19) AAV patients. Data are
presented as boxplots with whiskers from minimum to maximum. C, Left: the histogram shows an exemple of CD62 staining on pDC from a control
subject (empty histogram) and an AAV patient in acute phase (grey histogram) as compared to isotype control (dotted line); Right: CD62L expression
on pDC and mDC is shown as MFI of CDL62 – MFI of isotype control. Data are presented as boxplots with whiskers from minimum to maximum.
doi:10.1371/journal.pone.0018734.g001
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control and vice versa. At a ratio of 1:1 HC Treg suppressed patient
effector cells by 72% (compared with 75% inhibition of autologous
HC effector T cells), whereas patient Treg cells were able to
suppress HC effector cell proliferation by only 45% (39% of
autologous effector cells). This indicates that the suppressive
function of Treg from AAV patients was indeed intrinsically
defective (Fig. 4D).
Lack of Th17 deviation in AAV
Finally, we sought to determine whether the defective Treg
function observed in AAV patients could be associated with a Th17
deviation. The in vitro production of IL-17 by patients and control
CD4
+ T cells subsets after 4 days of stimulation by anti-CD3+CD28
mAbs was assessed.Asshown inFig.5,thelevels ofIL-17 produced
byCD4
+CD25
2 T cellswerenot statisticallydifferentbetween the 3
groups although there was a tendency to higher IL-17 secretion by
T cells from acute phase patients. CD4
+CD25
highCD127
low/2
produced less IL-17 than CD25
2CD4
+ T cells, again with no
significant difference between the three groups. Finally, co-culture
of Treg with effector T cells did not result in the suppression of IL-
17 production in any group. We also assessed the intracellular
expression of IL-17 in CD4+ T cells by flow cytometry after
polyclonal stimulation (PMA + ionomycine) of frozen PBMCs, and
again found no differences between controls and patients (data not
shown). Therefore, our data suggest that the defect in suppressive
function of Treg in AAV patients is not associated with a Th17
deviation.
Discussion
Dendritic cells and Treg have been shown to play critical roles
in the control and pathogenesis of autoimmune diseases. To our
knowledge, this is the first report on the frequency and phenotype
of circulating DC in AAV. Both mDC and pDC numbers were
reduced in AAV patients during acute phase and even, although at
Figure 2. Characterization of Treg using flow cytometry in controls and patients. A, Expression of CD25, CD127 and FOX-P3 in CD4
+ T cells.
Representative dot plots for healthy controls (HC), AAV patients in remission phase (AAV-RP) and AAV patients in acute phase (AAV-AP) showing
CD25 vs. CD127 and CD25 vs. FOXP3 expression in gated CD4
+CD3
+ T cells are shown. The gate use to identify Treg in fresh blood is shown in each
CD25 vs. CD127 dot plot. B. Representative histograms showing expression of FOX-P3 (bold line) vs. isotype control (dotted line) and CD39 (inset) in
CD4
+CD25
highCD127
low cells as gated in A.
doi:10.1371/journal.pone.0018734.g002
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Treg function is impaired in AAV during remission and more
importantly, showed that this function is even more dramatically
reduced in acute phase patients that did not received any
immunosuppressive drug.
Animal models have shown that DC play a pivotal role in the
induction and in the maintenance of peripheral T cell tolerance.
Various mechanisms have been demonstrated such as induction of
anergy, deletion or regulatory T cells. Moreover, DC were also
shown to control the function of naturally induced regulatory T
cells (Treg) during immune response. The role of T cells in the
induction of AAV has been suggested by many studies [4]. A
reduction in circulating DC subset numbers have been observed in
various autoimmune diseases such as systemic lupus erythematosus
[31,32], celiac disease [33] rheumatoid arthritis and psoriatic
arthritis [34,35]. Such a decrease in circulating DC could be
related to a reduction of DC differentiation from bone marrow
progenitors, to a reduced global half-life of DC or to a recruitment
of blood DC to either lymphoid or non lymphoid tissues. A
significant decrease in DC numbers was observed in AAV patients,
both during the acute phase and the remission phase. However,
the phenotype of both mDC and pDC from remission patients,
which can be defined as semi mature, was not different from that
observed in healthy donors. Interestingly, during the acute phase
the decrease in the number of DC was more pronounced, and was
associated with an increase in CD62L expression. Because CD62L
was previously shown to mediate pDC migration to lymph nodes
[28], this altered phenotype in AAV patients could favor their
recruitment in secondary lymphoid organs. The role of CD62L in
circulating mDC migration remains to be established. In contrast
to our results, expression of CD62L was reduced on DC from
patients with psoriatic arthritis and with rheumatoid arthritis [34],
indicating that variation in CD62L expression in AAV patients
can not be simply related to inflammatory process. A recent study
suggests that immature DC are recruited in the kidneys of AAV
patients, and then cluster with T cells in the interstitial infiltrate
[36]. Therefore, the reduced DC numbers we observed during the
acute phase could be related to their recruitment in secondary
lymphoid organs and/or in inflammatory tissues. It is interesting
to note that this feature persisted during remission although a role
for low doses of corticosteroids in reducing DC numbers is
possible. Once in secondary lymphoid organs, it is possible that
DC could modulate T-cell responses during AAV. Other
mechanisms that could explain this decreased DC numbers, i.e
as defective DC differentiation, and decreased DC half-life still
need to be explored.
Treg suppress the activation of conventional T cells in vitro and
play a key role in vivo in regulating the immune responses that
drive autoimmune diseases. Abdulahad et al reported that WG
patients in remission exhibited an increase in the proportion of
memory-like Treg (FOXP3
+, CD25
high, CD45RO
+) among CD4
+
T cells that are functionally defective [13]. The absolute numbers
Figure 3. Frequency, number and phenotype of Treg in patients vs. controls. Histograms represent: A,P r o p o r t i o no f
CD4
+CD25
highCD127
low/2 T cells within CD4
+CD3
+ T cells (as gated in figure 2A) for HC (mean, 6.8%, n=18), remission, (mean, 6.9%, n=15), and
acute (mean, 6.7%, n=19) AAV patients. No significant difference was observed for percentage of Treg cells between the 3 groups. B, Absolute
numbers of CD4
+CD25
highCD127
low/2 T cells in whole blood for HC (mean, 60.3 cells/mL), remission (mean, 47.5 cells/mL), and acute (mean, 40.1cells/
mL) AAV patients. C, MFI of FOX-P3 in gated Treg and D, Mean percentage of CD39
+ cells within Treg. Data are presented as boxplots with whiskers
from minimum to maximum.
doi:10.1371/journal.pone.0018734.g003
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by immunosuppressive treatments. However, the authors suggest-
ed that these FOXP3
+ CD25
high cells could be chronically
activated T cells rather than true Treg. In contrast, we observed
a moderate decrease in the absolute numbers of circulating Treg
in acute phase patients, whereas their proportion among CD4
+ T
cells were not modified when compared to healthy controls. These
discrepancies might be related to the fact that we performed our
study on whole blood and used the CD25 and CD127 markers to
identify Treg, whereas Abdulahad et al. used PBMC, with CD25
and FOXP3
+ as markers. It should be noted that the moderate
decrease in Treg numbers in AAV patients was likely due to the
global lymphopenia that is usually observed in these patients,
especially during flares, whereas the frequency of Tregs within the
CD4 compartment was similar to that of controls. We further-
more found that the expression level of FOXP3
+ in CD3
+
CD4
+CD25
highCD127
low/2 cells was similar in AAV patients and
controls. More importantly, the ex vivo suppressive function of
Treg from AAV patients was defective. In remission patients
without immunosuppressive therapy or with low dose of corti-
costeroids only, this defect was actually moderate; therefore our
results confirm the previous studies that showed a defective Treg
function in WG patients and extend this finding to non WG AAV
[13,37,38]. In addition, this defect was more dramatic during
acute phase. Importantly, these patients were analysed before the
administration of any immunosuppressive drugs which could
obviously strongly modify in vitro assays.
There are controversies regarding the assessment of suppressive
function of Treg in autoimmune diseases, which clearly depends
on the markers used to sort Treg. For instance, in multiple
sclerosis, Treg cells isolated by CD4
+CD25
high expression had
impaired function [39], but Treg cells defined as CD4
+
CD25
highCD127
low/2 had the same suppressive function com-
pared to controls [40]. In fact, a general increase in CD25
expression in T cells has been reported in various inflammatory
diseases including AAV [12,30]. Therefore, CD25 is not a suitable
marker by itself to identify Treg in human [41]. Moreover,
FOXP3 may also be transiently upregulated in human activated
Figure 4. Suppressive function of circulating T regulatory cells. A, Gating strategy for Treg sorting and typical results after sorting.
B, Proliferative responses of Treg, effector responder T cells and Treg:Tresp co-cultures (ratio1/1) upon CD3+CD28 stimulation. Histograms are
expressed as mean value +/2 SD of cpm for healthy controls (HC ; n=18), remission patients (RP ; n=15), and active patients (PA ; n=19). C, The
percentage of suppression of responding cells was determined as 12(proliferation of co-culture/proliferation of responder population alone)6100.
Data are presented as boxplots with whiskers from minimum to maximum. D, A suppressive assay mixing Treg and effector T cells from and AP
patient and a healthy volunteer was performed. Black bars represent suppression with HC Treg, and white bars with patient Treg. The results of one
experiment out of three with similar results are shown.
doi:10.1371/journal.pone.0018734.g004
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CD25 and CD127 expression, which was shown to help
discriminating Treg from effector T cells [43]. However, CD127
could also be down regulated on activated effector T cells [41].
Although we could therefore not completely exclude that sorted
Treg might be contaminated by small numbers of effector T cells,
it should be noted that CD25 expression was not upregulated in
AAV remission patients and that their CD25/CD127 profiles were
similar to that observed in controls. Yet, even in these patients, the
in vitro suppressive activity of sorted Tregs was strongly reduced as
compared to controls. Additional studies are necessary to correlate
this impaired suppressive function with a more detailed phenotype
of Treg in AAV patients together with potential changes in FOX-
P3
+ Treg subset representation [41].
These results point to a possible role for Treg functional
deficiency in the pathogenesis of AAV and relapses. Development
of naturally occurring Treg cells occurs in the thymus, and their
maintenance and homeostasis possibly depends on the recognition
of auto-antigens presented by DC in peripheral lymphoid organs.
The suppressive mechanisms by which Treg cells exert their
inhibitory effects in vitro were found to be dependent on a direct
T-regulatory/T-effector cell contact. The inhibitory effect itself is
antigen nonspecific but requires antigen-dependent activation of
the regulatory T cells through their T-cell receptor. In this respect,
antigen presenting cells play a crucial role in activation of Treg,
and previous studies have shown that DC can actually control
Treg function [44,45,46,47]. Murine immature DC were shown to
induce Treg suppressive activity in vitro whereas following DC
maturation induced by TLR ligation, Treg suppressive activity
was inhibited [48]. However, mature DC are potent inducers of
Treg proliferation, and mature–DC expanded Treg appeared to
retain their suppressive activity [46,49]. This is consistent with the
fact that costimulation signals are essential to survival of functional
Tregs in vivo [50]. In fact, recent murine data indicate that, in
vivo, the numbers of Treg are crucially dependent on the numbers
of DC [51]. The recent description of a new syndrome of DC,
monocyte and NK lymphoid deficiency in human supported this
role of DC in Treg homeostasis [52]. Indeed, in these patients, the
lack of DC was associated with a strongly reduced numbers of
circulating Treg. Finally, it is possible that conventional and
plasmacytoid DC have different roles in regulating Treg
homeostasis and functions [53]. How this DC-Treg feedback loop
is affected during inflammatory diseases remains to be determined.
Importantly, the defect of suppressive activity in AAV patients
was Treg-intrinsic and not related to a relative resistance of
effector T cells to Treg-mediated suppression. Several studies have
shown that Treg can be separated into subsets based on the
expression of markers such as CD103, ICOS or CD39
[20,54,55,56]. It was shown that CD39
+ but not CD39
2 Treg
were able to suppress Th17 activation, and that CD39
+ Treg were
decreased in multiple sclerosis patients [21]. However, we showed
here that this is not the case in AAV patients. Th17 cells, which
are a subset of effector CD4+ T cells specialized in the production
of IL-17 and IL-22 and in recruitment and activation of
neutrophils, have been implicated in autoimmune diseases,
including multiple sclerosis, lupus and diabetes [57]. A recent
study suggested that T cells from ANCA-positive WG patients also
exhibited a skewed Th17 response following stimulation with the
auto-antigen PR3 [58]. More recently, Nogueira et al reported an
increase in the level of IL-17 and IL-23 in the sera of AAV patients
[59]. This is a tempting hypothesis as it is well known that Treg
and Th17 are developmentally related [60,61,62,63]. We further
assessed this Th17/Treg balance hypothesis, by analysing the
production of IL-17 by effector T cells from AAV patients
following polyclonal stimulation. We could not find any evidence
of Th17 deviation, both in remission and in acute phase patients.
Therefore the possible role of Th17 in AAV needs to be clarified
by further studies.
In conclusion, we demonstrated that DC numbers, as well as
Treg suppressive activity, are significantly reduced in untreated
patients with AAV in a disease activity specific manner. The
decrease in Treg suppressive function might be related to changes
in DC function, and might be an important defective tolerance
checkpoint in AAV.
Figure 5. Concentration of IL-17 in co-culture supernatants. IL-17 was quantified in supernatant using a multiplex fluorescent bead
immunoassay: the levels of IL-17 produced by Treg, responder T cells and co-culture were not statistically different between the 3 groups.
doi:10.1371/journal.pone.0018734.g005
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Study population
Blood samples from 19 untreated patients with AAV in acute
phase (AP) with a BVAS above 3 (Birmingham Vasculitis Activity
Score), 15 AAV patients in remission (RP, BVAS,3) and 18 age-
matched healthy controls (HC) were analysed (Table 1). The
diagnosis of AAV was established according to the Chapel Hill
criteria, and all patients had ANCAs at this time. For patients in
acute phase, either at presentation or during relapse, samples were
drawn before any immunosuppressive therapy (included cortico-
steroids). Patients in remission included in this study either did not
receive any immunosuppressant (11/15) or received corticoste-
roids only with a maximum dosage 10 mg/d (4/15).
Ethics statements: all patients and healthy controls provided
written informed consent. Internal board and the local medical
ethics committee (Comite ´ de Protection des Personnes Ouest IV,
Nantes) reviewed and specifically approved the study.
Dendritic cells and regulatory T cells characterisation
Circulating dendritic cells and regulatory T cell numbers were
measured by flow cytometry on fresh whole blood within 24 h
after sampling. Whole blood cells were incubated with monoclonal
antibodies (mAbs) followed by erythrocyte lysis with FACS lysing
solution (BD Biosciences, San Jose, CA, USA) at room
temperature. After washing with PBS, events were analysed in a
LSRII cytometer (BD Biosciences). Absolute counts of lympho-
cytes/monocytes and CD4 lymphocytes were determined with BD
Multitest
TMCD3/CD8/CD45/CD4 in BD Trucount
TM Tubes.
To identify dendritic cells, a six-color flow cytometry assay was
performed with the following mouse anti-human mAbs: fluorescein
isothiocyanate (FITC)-conjugated lineage cocktail-1 Abs (Lin 1),
Am Cyan conjugated anti-CD45 (clone HI30), Allophycocyanin
(APC)-conjugated CD11c (clone S-HCL-3), phycoerythrin-cyanin5
(PECy5)-conjugated anti-CD123 (clone 9F5), Allophycocyanin
cyanin7 (APC-Cy7)-conjugated anti-HLA-DR (clone L243) and
Phycoerythrin (PE)-conjugated with CD86 (clone 2331), CD62L
(clone DREG56), CCR7 (clone 150503) or IgG (1+2a) (all from BD
Biosciences, except CCR7, R&D systems, Minneapolis, MN, USA
and IgG (1+2a)-PE from Beckman Coulter, Miami FL). The Lin1
contained several mAbs: CD3 (T cells; clone SK7), CD14
(monocytes/macrophages; clone MWP9), CD16 (natural killer cells;
clone 3G8), CD19 (B cells; clone SJ25C1), and CD56 (natural killer
cells, clone NCAM16.2). Dendritic Cells were identified as
Lin
2HLA-DR
+ cells within a lymphocytes-monocytes gate.
CD11c and CD123 expression was determined within Lin
2HLA-
DR
+ cells in order to define myeloid DC (CD11c
+CD123
2)a n d
plasmacytoidDC(CD11c
2CD123
+) subsets.AbsoluteDCnumbers
were calculated from the lymphocyte-monocyte counts. In each
subtype, we analysed the percentage and the expression level of
CD86, CD62L and CCR7. The expression levels were calculated
by subtracting the mean fluorescence intensity (MFI) of the isotype
from the MFIs of each marker (Fig. 1A).
Treg cells were identified with Peridinin chlorophyl protein
(PerCP)-conjugated anti-CD45 (clone 2D1), Phycoerythrin (PE)-
conjugated anti-CD127 (clone SB/199), phycoerythrin-cyanin7
(PC7)-conjugated anti CD25 (clone 2A3), and fluorescein isothio-
cyanate (FITC)-conjugated anti-CD3 (cloneSK7), all from BD
Biosciences, and Allophycocyanin-H7 (APC-H7)-conjugated anti-
CD4 (clone 13B8.2) from Beckman Coulter. Treg were identified as
CD45
+CD3
+CD4
+CD25
highCD127
low/2. The number of Treg
were deduced from the CD4 T cells number multiplied by the
proportion of regulatory T cells in CD4 cells. To assess the
expression of FOXP3 and CD39 in Treg, frozen PBMC were
labelled with CD4-APC-H7, CD127-FITC, CD25-PC7 (same
clone as above) and CD39-APC (clone TU66), all antibodies from
BD Biosciences, followed by fixation, permeabilization, and
intracellular staining with FOXP3 mAb (clone PCH101, eBios-
ciences, San Diego, CA) according to the manufacturer’s instruc-
tions (Fig. 2). This last staining on PBMC was performed on 10
Healthy controls, 10 patients with AAV in acute phase, and 10
patients with AAV in remission.
CD4
+CD25
2, CD4
+CD25
highCD127
low/2 Cell sorting
PBMCs were isolated from EDTA whole blood by density
centrifugation over Ficoll-Paque (Eurobio). 45610
6 freshly isolated
PBMC were incubated for 10 min in 100 mL of PBS- EDTA with
anti-CD4 FITC (clone RPA-T4 BD biosciences), CD127 PE (clone
SB/199 BD biosciences) and anti-CD25 AlexaFluor 647 (in house
clone 33B3.1 conjugated to AF647 using a kit from Invitrogen).
Human CD4
+CD25
2 (Responder T cells) and CD4
+CD25
high
CD127
low/2 were then separated using a high-speed cell sorter
(FACSAria; BD Biosciences). Purity was routinely .98% for Treg
and .99% for CD4+CD252 T cells (Fig. 3A).
In vitro suppression assay
Suppressive function of Treg was determined by co-culture
assay, with all experiments performed on fresh peripheral blood
lymphocytes. To assess the functional activity of T regulatory cells,
2610
4 responder cells were co-cultured for 4 days with 2610
4
Treg cells (ratio 1:1) in complete RPMI 1640 medium supple-
mented with HEPES, L-glutamine, penicillin, streptomycin,
sodium pyruvate, non-essential amino acids, and 10% human
AB serum. All assays were performed in anti-CD3 (Orthoclone
Table 1. Clinical features of patients.
Patients in remission (BVAS,3) Patients in acute phase (BVAS.3) Healthy controls
Mean age (years) 58 57 55
Wegener’s granulomatosis 11 14 -
ANCA anti-PR3 7 11 -
ANCA anti-MPO 4 3 -
Microscopic polyangiitis 4 5 -
ANCA anti-PR3 - - -
ANCA anti-MPO 3 5 -
Patient number 15 19 18
doi:10.1371/journal.pone.0018734.t001
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a final volume of 200 mL of complete medium, with soluble anti-
CD28 at 5 mg/ml (clone CD28.2 BD Biosciences). After 4 days of
culture, the cells were pulsed with 1 mCi per well of
3H-thymidine
(Amersham Biosciences) for 8 hours. The cells were then harvested
and counted in a scintillation counter.
3H-thymidine incorporation
was measured as cpm. The percentage of suppression of the
responding cell proliferation was determined as 12(mean cpm of
co-culture/mean cpm of responder alone)6100.
Cytokines
IL-17 was measured in supernatants of co-culture 4 days after
the initiation using a multiplex fluorescent bead immunoassay
(Biosource) together with a Luminex cytometer. For this
experiment, supernatants of 10 HC, 14 RP and 11 AP were
analysed.
Statistical analysis
Statistical comparisons between pairs of experimental groups
were performed using the Mann-Whitney U-test for unpaired
data, and a P-value of less than 0.05 was considered statistically
significant. Data are presented as boxplots with whiskers from
minimum to maximum.
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